Sunakiment vs WIN378

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: TSLP · full Asthma pipeline

Sunakiment

Developed by AstraZeneca and partners

Phase 2 in Asthmaantibody fragment
Partial signal

NCT06529419 · Phase 2 · completed

The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.

Reported efficacy

Part A and Part B: Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)); Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Terminal rate constant (λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)): Primary outcome, adverse events in Part A (healthy adults) and Part B (asthma): acceptable safety profile, low incidence of treatment-induced antidrug antibodies (part A n=1; part B n=2); safety outcome, no formal efficacy test. The other registered primaries are pharmacokinetic. Secondary outcome, FeNO change vs placebo at day 28 in Part B: 23% reduction with 8 mg (P=.037). (not_applicable)

Result source: NCT05110976

WIN378

Developed by Windward Bio and partners

Phase 2/3 in Asthmamonoclonal antibody
Weak signal

NCT05790694 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events" (with 6 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2028 · NCT07120503 (registry estimate)

Reported efficacy

Adverse events (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-AUC0-last (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Tmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Cmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-CL/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Vd/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-T1/2 (Strat of Treatment to end of study (approsimately 160days)): In 50 healthy adults given single doses of 20, 60, 200, 600 or 900 mg (eight on drug and two on placebo at each level), treatment-emergent adverse events were comparable between dose groups and placebo, with no trend for increasing risk with dose escalation. Anti-drug antibody incidence was 5% (2 of 40), no injection site reactions occurred, mean half-life ranged from 55.0 to 65.8 days, and exposure increased in a near dose-proportional manner from 20 to 900 mg.

Result source: NCT05790694

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSunakimentWIN378
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
ACQ-5, change—Not reported—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

Sunakiment
—Not reported
WIN378
—Not reported

Trough FEV1, change

Sunakiment
—Not reported
WIN378
—Not reported

ACQ-5, change

Sunakiment
—Not reported
WIN378
—Not reported

OCS dose reduction

Sunakiment
—Not reported
WIN378
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Sunakiment: no structured comparison results are available for Asthma.

WIN378: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sunakiment's landscape · WIN378's landscape